Javascript must be enabled to continue!
Characterizing “no treatment” decisions in patients with advanced-stage cancers.
View through CrossRef
76 Background: Cancer (CA) is one of the leading causes of death worldwide. In 2020 CA was the second leading cause of mortality in the US. Novel treatments for various malignancies are discovered each passing year. Despite these advancements, some patients refuse to receive treatment. Our study focused on characterizing the group of patients with advanced malignancies who refused therapy. Methods: We performed a retrospective chart review of patients diagnosed with advanced malignancies, aged 18-75 years, between 01/01/ 2010 and 12/31/2015, who refused any therapy. We used Geisinger Health System’s data. Results: Our search provided 644 patients who met our inclusion criteria. The mean age of patients was 63.2 years (standard deviation (σ) 8.3). Female patients made up 40.4% (260/644), while 59.6% (384/644) were male. Most patients were Caucasian (96.9%, 624/644), 1.9% (12/644) were Black; 0.6% (4/644) were Asian, and 0.6% (4/644) were of unknown racial background. Marital status was evenly distributed with 50.0% (322/644) being married and 50.0% (322/644) being non-married. Most of the study population (52.3%, 337/644) had government-funded insurance at the time of CA diagnosis; 46.6% (300/644) had private insurance, and 1.1% (7/644) had no insurance. Stage 3 disease, according to American Joint Committee on Cancer staging was noted in 21.1% (136/644), while 78.9% (508/644) had stage 4 disease. The mean BMI was 28.2 (σ 8.3). Most patients were either overweight or obese (60.6%, 350/577; 67 patients did not have data on BMI available). A history of cigarette smoking was present in 73.0% (438/600). Adenocarcinomas (323/639, 50.5%) were the most prominent histological subtype. The most common site of malignancy was the respiratory system (220/644, 34.2%). Only 9.6% (62/644) of patients had a history of previous CA, while a family history of CA was present in 29.5% (190/644). Most patients (62.1%, 400/644) had a Charleston Comorbidity Index (CCI) > 5; the mean CCI was 6.4 (σ 3.7). In 17.1% (110/644) a palliative medicine referral was made. Substance use disorders were present in 23.8% (153/644); 14.4% (93/644) had a history of depression, and anxiety 10.1% (65/644). Conclusions: Male patients made up a larger proportion of the group of advanced-stage patients who declined therapy. The racial distribution in this group of patients appeared to reflect the local population. Most patients who refused therapy had stage 4 disease, and they appeared to have severe underlying comorbidities, with an average CCI >5. Despite treatment refusal, a surprisingly low percentage of patients were referred to palliative medicine.[Table: see text][Table: see text]
American Society of Clinical Oncology (ASCO)
Title: Characterizing “no treatment” decisions in patients with advanced-stage cancers.
Description:
76 Background: Cancer (CA) is one of the leading causes of death worldwide.
In 2020 CA was the second leading cause of mortality in the US.
Novel treatments for various malignancies are discovered each passing year.
Despite these advancements, some patients refuse to receive treatment.
Our study focused on characterizing the group of patients with advanced malignancies who refused therapy.
Methods: We performed a retrospective chart review of patients diagnosed with advanced malignancies, aged 18-75 years, between 01/01/ 2010 and 12/31/2015, who refused any therapy.
We used Geisinger Health System’s data.
Results: Our search provided 644 patients who met our inclusion criteria.
The mean age of patients was 63.
2 years (standard deviation (σ) 8.
3).
Female patients made up 40.
4% (260/644), while 59.
6% (384/644) were male.
Most patients were Caucasian (96.
9%, 624/644), 1.
9% (12/644) were Black; 0.
6% (4/644) were Asian, and 0.
6% (4/644) were of unknown racial background.
Marital status was evenly distributed with 50.
0% (322/644) being married and 50.
0% (322/644) being non-married.
Most of the study population (52.
3%, 337/644) had government-funded insurance at the time of CA diagnosis; 46.
6% (300/644) had private insurance, and 1.
1% (7/644) had no insurance.
Stage 3 disease, according to American Joint Committee on Cancer staging was noted in 21.
1% (136/644), while 78.
9% (508/644) had stage 4 disease.
The mean BMI was 28.
2 (σ 8.
3).
Most patients were either overweight or obese (60.
6%, 350/577; 67 patients did not have data on BMI available).
A history of cigarette smoking was present in 73.
0% (438/600).
Adenocarcinomas (323/639, 50.
5%) were the most prominent histological subtype.
The most common site of malignancy was the respiratory system (220/644, 34.
2%).
Only 9.
6% (62/644) of patients had a history of previous CA, while a family history of CA was present in 29.
5% (190/644).
Most patients (62.
1%, 400/644) had a Charleston Comorbidity Index (CCI) > 5; the mean CCI was 6.
4 (σ 3.
7).
In 17.
1% (110/644) a palliative medicine referral was made.
Substance use disorders were present in 23.
8% (153/644); 14.
4% (93/644) had a history of depression, and anxiety 10.
1% (65/644).
Conclusions: Male patients made up a larger proportion of the group of advanced-stage patients who declined therapy.
The racial distribution in this group of patients appeared to reflect the local population.
Most patients who refused therapy had stage 4 disease, and they appeared to have severe underlying comorbidities, with an average CCI >5.
Despite treatment refusal, a surprisingly low percentage of patients were referred to palliative medicine.
[Table: see text][Table: see text].
Related Results
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Early-Onset Gastrointestinal Cancers
Early-Onset Gastrointestinal Cancers
ImportanceEarly-onset gastrointestinal (GI) cancer is typically defined as GI cancer diagnosed in individuals younger than 50 years. The incidence of early-onset GI cancer is risin...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Abstract A21: Lung cancer surveillance with CT scan and autofluorescence bronchoscopy
Abstract A21: Lung cancer surveillance with CT scan and autofluorescence bronchoscopy
Abstract
Background: More than 75% of lung cancer patients are diagnosed at an advanced stage, when the survival rate is less than 15%. Sputum cytology, x-ray and CT...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...

